查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028390

難治型憂鬱症治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Treatment- Resistant Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

難治型憂鬱症(TRD) 治療市場的成長要素

由於重度憂鬱症負擔日益加重以及對先進治療方案的需求不斷成長，全球難治性憂鬱症治療市場正經歷顯著成長。預計到2025年，該市場規模將達到24億美元，2026年將成長至26.7億美元，到2034年將達到61.5億美元，預測期內複合年成長率（CAGR）為11.00%。北美地區憑藉其完善的醫療保健基礎設施和創新治療方法的日益普及，預計將在2025年佔市場主導地位，市場佔有率高達53.51%。

難治性憂鬱症是指患者對至少兩種抗憂鬱症治療反應不佳的情況。這與複雜的生物學和心理學因素有關，例如神經傳導物質功能障礙、發炎反應和異常神經活動。日益成長的應對重度憂鬱症和降低自殺風險的需求是推動市場擴張的主要因素。

市場動態

成長要素

市場成長的主要促進因素是全球難治性憂鬱症盛行率的不斷上升。有相當一部分重度憂鬱症患者對傳統治療方法沒有反應，因此對先進治療方法的需求十分旺盛。

另一個重要因素是製藥公司加大研發投入。領先的製藥公司正積極開發創新治療方法，包括抗憂鬱症和新型藥物，以滿足尚未滿足的醫療需求。臨床試驗的增加和監管核准的擴大正在加速有效治療方法的上市。

此外，人們對心理健康的認知不斷提高，社會對心理健康的歧視也逐漸減少，促使更多患者尋求治療。新興經濟體醫療保健服務的改善和宣傳宣傳活動的發展，也進一步推動了市場成長。

市場限制因素

儘管取得了這些積極進展，市場仍面臨許多挑戰，例如缺乏針對難治性憂鬱症（TRD）的標準化治療指南。診斷和治療方法的差異往往導致患者療效不一致。

此外，治療選擇有限和治療中斷率高阻礙了市場擴張。患者常常因為起效延遲或療效不足而停止治療，影響了長期治療的持續性。

市場趨勢

市場的主要趨勢之一是從傳統的口服抗憂鬱症轉向其他給藥途徑，例如鼻內或靜脈注射。這些方法起效更快，有些治療方法甚至在數小時內而非數週內就能見效。

另一個重要趨勢是NMDA受體拮抗劑（如esketamine）的使用增加。這些治療方法能迅速緩解症狀，並正獲得醫療專業人員的支持。

此外，藥物開發平臺的創新正在市場上不斷擴展，各公司專注於個人化醫療和標靶治療，以改善治療效果。

細分分析

就藥物類型而言，抗憂鬱症藥物佔市場主導地位，其中選擇性血清素再攝取抑制劑（SSRIs）和選擇性血清素和去甲腎上腺素再攝取抑制劑（SNRIs）被廣泛用作第一線治療藥物。這些藥物仍然是治療憂鬱症最常使用的製劑。

預計 NMDA 細分市場將呈現最高的成長率，這得益於創新治療方法（如esketamine滴鼻劑）的日益普及以及旨在快速緩解症狀的強大臨床研發管線。

就分銷管道而言，醫院藥房佔最大佔有率，因為許多難治性憂鬱症的治療需要醫療監督和處方箋配藥。

雖然實體藥局因其便利性也做出了重大貢獻，但受數位化進步和患者便利性提高的推動，網路藥局領域預計將經歷最快的成長。

區域洞察

受疾病高發生率、健全的報銷制度和持續的藥物核准的推動，北美預計將引領全球市場，到 2025 年達到 12.9 億美元，到 2026 年達到 14.3 億美元。

歐洲佔第二大佔有率，這得益於研發投入的增加以及旨在改善精神衛生保健的有利監管措施。

由於公眾意識的提高、醫療基礎設施的改善以及診斷率的提高，亞太地區預計將保持穩定成長。中國和印度等國家對高級精神病治療的需求日益成長。

否則，在醫療保健支出增加和精神衛生服務逐步改善的支持下，預計將保持溫和成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家/地區難治性憂鬱症盛行率
  • 抗精神病藥物研發最新趨勢概述
  • 管道分析：主要公司
  • 重大工業發展、合併、收購等。
  • 新冠疫情對市場的影響

第5章：2021-2034年全球難治性憂鬱症治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類型分類
    • N-甲基-D-天門冬胺酸（NMDA）
    • 抗憂鬱症
    • 抗精神病藥物
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他

第6章：北美難治性憂鬱症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲難治性憂鬱症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第8章：亞太地區難治性憂鬱症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 其他亞太地區

第9章：其他難治性憂鬱症治療市場分析、洞察與預測（2021-2034年）

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Eli Lilly and Company
    • GlaxoSmithKline
    • Pfizer Inc.
    • Janssen Pharmaceuticals
    • AbbVie Inc.
    • AstraZeneca
    • H. Lundbeck
    • Sandoz International GmbH
    • Par Pharmaceutical Companies Inc.
    • Otsuka Holdings Co., Ltd.
Product Code: FBI102820

Growth Factors of treatment-resistant depression (TRD) treatment Market

The global treatment-resistant depression (TRD) treatment market is experiencing notable growth due to the rising burden of major depressive disorders and the need for advanced therapeutic solutions. The market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.67 billion in 2026, reaching USD 6.15 billion by 2034, expanding at a CAGR of 11.00% during the forecast period. North America dominated the market with a 53.51% share in 2025, driven by strong healthcare infrastructure and increasing adoption of innovative therapies.

Treatment-resistant depression occurs when patients fail to respond adequately to at least two antidepressant therapies. It is associated with complex biological and psychological factors such as neurotransmitter dysfunction, inflammatory responses, and abnormal neural activity. The growing need to address severe depression cases and reduce suicide risks is significantly contributing to market expansion.

Market Dynamics

Growth Drivers

The primary driver of market growth is the increasing prevalence of treatment-resistant depression globally. A significant portion of patients with major depressive disorder do not respond to conventional therapies, creating a strong demand for advanced treatment options.

Another key factor is the rising investment in research and development by pharmaceutical companies. Leading players are actively developing innovative therapies, including rapid-acting antidepressants and novel drug classes, to address unmet clinical needs. Increased clinical trials and regulatory approvals are accelerating the availability of effective treatments.

Additionally, the growing awareness of mental health and reduction in social stigma are encouraging more patients to seek treatment. Improved healthcare access and awareness campaigns in emerging economies are further supporting market growth.

Market Restraints

Despite positive growth trends, the market faces challenges such as the lack of standardized treatment guidelines for managing TRD. Variability in diagnosis and treatment approaches often leads to inconsistent patient outcomes.

Moreover, limited therapeutic options and treatment discontinuation rates hinder market expansion. Patients often drop out due to delayed drug effectiveness or inadequate results, affecting long-term treatment adoption.

Market Trends

A major trend in the market is the shift from traditional oral antidepressants to alternative routes of administration, such as intranasal and intravenous therapies. These methods offer faster onset of action, with some treatments showing improvements within hours instead of weeks.

The increasing adoption of NMDA receptor antagonists, such as esketamine, is another significant trend. These therapies provide rapid symptom relief and are gaining traction among healthcare providers.

Furthermore, the market is witnessing growing innovation in drug development pipelines, with companies focusing on personalized medicine and targeted therapies to improve treatment outcomes.

Segmentation Analysis

By drug type, the antidepressants segment dominates the market due to widespread use of SSRIs and SNRIs as first-line treatments. These drugs remain the most commonly prescribed options for managing depression.

The NMDA segment is expected to grow at the fastest rate, driven by increasing adoption of innovative therapies such as esketamine nasal spray and strong clinical pipelines targeting rapid symptom relief.

By distribution channel, the hospital pharmacies segment holds the largest share, as most TRD treatments require medical supervision and prescription-based dispensing.

Retail pharmacies also contribute significantly due to accessibility, while the online pharmacies segment is expected to witness the fastest growth, supported by increasing digitalization and patient convenience.

Regional Insights

North America leads the global market, with a value of USD 1.29 billion in 2025 and USD 1.43 billion in 2026, driven by high disease prevalence, strong reimbursement systems, and continuous drug approvals.

Europe holds the second-largest share, supported by increasing R&D investments and favorable regulatory initiatives aimed at improving mental healthcare.

Asia Pacific is expected to grow at a steady pace due to rising awareness, improving healthcare infrastructure, and increasing diagnosis rates. Countries such as China and India are witnessing growing demand for advanced psychiatric treatments.

The rest of the world is projected to grow moderately, supported by rising healthcare expenditure and gradual improvements in mental health services.

Competitive Landscape

The market is highly competitive, with key players such as Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Janssen Global Services, and AbbVie Inc. leading the industry. These companies are focusing on research collaborations, clinical trials, and product innovation to strengthen their market presence.

Recent developments include multiple Phase II and Phase III clinical trials, new drug approvals, and increased investments in innovative therapies targeting treatment-resistant depression.

Conclusion

The treatment-resistant depression treatment market is poised for significant growth, driven by increasing disease prevalence, advancements in drug development, and rising awareness of mental health. Although challenges such as lack of standardized guidelines and limited treatment options persist, ongoing innovation and strong R&D investments are expected to transform the market landscape and improve patient outcomes in the coming years.

Segmentation By Drug Type

  • N-methyl-D-aspartate (NMDA)
  • Antidepressants
  • Antipsychotics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, and the Rest of Europe)
  • Asia Pacific (China, India, Japan, Australia, and the Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Treatment-Resistant Depression, By Key Countries/Regions, 2025
  • 4.2. Overview of Current Advances in R&D for Antipsychotic Drugs
  • 4.3. Pipeline Analysis: Key Players
  • 4.4. Key Industry Developments, Mergers, Acquisitions, Etc.
  • 4.5. Impact of COVID-19 on Market

5. Global Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. N-methyl-D-aspartate (NMDA)
    • 5.1.2. Antidepressants
    • 5.1.3. Antipsychotics
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Drug Stores & Retail Pharmacies
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. N-methyl-D-aspartate (NMDA)
    • 6.1.2. Antidepressants
    • 6.1.3. Antipsychotics
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Drug Stores & Retail Pharmacies
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. N-methyl-D-aspartate (NMDA)
    • 7.1.2. Antidepressants
    • 7.1.3. Antipsychotics
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Drug Stores & Retail Pharmacies
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe

8. Asia Pacific Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. N-methyl-D-aspartate (NMDA)
    • 8.1.2. Antidepressants
    • 8.1.3. Antipsychotics
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Drug Stores & Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Rest of the World Treatment-Resistant Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. N-methyl-D-aspartate (NMDA)
    • 9.1.2. Antidepressants
    • 9.1.3. Antipsychotics
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Drug Stores & Retail Pharmacies
    • 9.2.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Eli Lilly and Company
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. GlaxoSmithKline
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Pfizer Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Janssen Pharmaceuticals
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. AbbVie Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. AstraZeneca
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. H. Lundbeck
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Sandoz International GmbH
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Par Pharmaceutical Companies Inc.
      • 10.2.9.1. Overview
      • 10.2.9.2. Products
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Otsuka Holdings Co., Ltd.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 5: North America Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 8: Europe Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 9: Europe Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 11: Asia Pacific Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Rest of the World Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: Rest of the World Treatment-Resistant Depression Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Treatment-Resistant Depression Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 3: Global Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 4: Global Treatment-Resistant Depression Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Treatment-Resistant Depression Treatment Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 6: North America Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2025
  • Figure 7: North America Treatment-Resistant Depression Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 8: North America Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 9: North America Treatment-Resistant Depression Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Treatment-Resistant Depression Treatment Market Value Share (%), By Country, 2025
  • Figure 11: Europe Treatment-Resistant Depression Treatment Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 12: Europe Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2025
  • Figure 13: Europe Treatment-Resistant Depression Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Treatment-Resistant Depression Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Treatment-Resistant Depression Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Treatment-Resistant Depression Treatment Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 18: Asia Pacific Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2025
  • Figure 19: Asia Pacific Treatment-Resistant Depression Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Treatment-Resistant Depression Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Treatment-Resistant Depression Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Rest of the World Treatment-Resistant Depression Treatment Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 24: Rest of the World Treatment-Resistant Depression Treatment Market Value Share (%), by Drug Type, 2025
  • Figure 25: Rest of the World Treatment-Resistant Depression Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Rest of the World Treatment-Resistant Depression Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: Global Treatment-Resistant Depression Treatment Market Share (%), By Company, 2025